Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01242488 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

A Phase 2 study of Rheumatoid Arthritis, sponsored by UCB Pharma.

Completed
Registry status
Phase 2
Development phase
221
Enrollment target
20
Study locations

NCT01242488: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by UCB Pharma.

NCT01242488 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by UCB Pharma. The registered enrollment target is 221 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01242488, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 2
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.

Conditions Studied

Interventions

  • BIOLOGICAL CDP6038
  • BIOLOGICAL Tocilizumab (Actemra or RoActemra)

Study Locations (20)

California

  • 127 - Covina
  • 148 - La Jolla
  • 184 - Long Beach
  • 177 - Los Angeles
  • 104 - Palo Alto
  • 149 - Sacramento
  • 158 - San Diego
  • 129 - Santa Maria
  • 164 - Upland
  • 107 - Wildomar

Arizona

  • 166 - Mesa
  • 154 - Paradise Valley
  • 118 - Scottsdale

Connecticut

  • 141 - Hamden
  • 137 - Norwalk
  • 101 - Trumbull

Arkansas

  • 103 - Hot Springs
  • 125 - Jonesboro

Delaware

  • 111 - Lewes

Florida

  • 176 - Aventura

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2010-11
Est. Completion 2012-06
Phase Phase 2
UCB Pharma

100 total trials

What the finished NCT01242488 record still lists

NCT01242488 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which CDP6038 is the first listed.

NCT01242488 names 20 study sites across 6 states, led by California, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01242488 about?

NCT01242488 is a clinical study titled "Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.

What is the current status of trial NCT01242488?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2010-11. Estimated completion is 2012-06.

What conditions does trial NCT01242488 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01242488?

The interventions under investigation include: CDP6038 (BIOLOGICAL), Tocilizumab (Actemra or RoActemra) (BIOLOGICAL).

Who is sponsoring clinical trial NCT01242488?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01242488 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01242488's enrollment target sits among peer trials

221 80th of 197 higher than 118 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03170440 · 221 participants · NA

    Non-invasive Nerve Stimulation for PTSD and Sleep

  • NCT04939610 · 222 participants · Phase 1

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

  • NCT05424783 · 222 participants

    MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

  • NCT05568264 · 222 participants · NA

    Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01242488, the US trial registry maintained by the National Library of Medicine. NCT01242488 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.